RecruitingNot ApplicableNCT04224064

Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas


Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle

Enrollment

158 participants

Start Date

Aug 26, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for a new blood test (biomarker) that could help doctors diagnose and monitor a rare type of cancer called liposarcoma (a cancer of fat tissue). Researchers will compare blood samples from liposarcoma patients to healthy volunteers. **You may be eligible if...** - You are 18 or older - You are having surgery for a liposarcoma (a fat-tissue cancer), including cases that have come back or spread, OR - You are a healthy person willing to donate a blood sample for comparison purposes - You are able to provide informed consent **You may NOT be eligible if...** - You have received chemotherapy or radiation before surgery for this cancer - You are pregnant or breastfeeding - You have had another cancer within the last 5 years (except certain skin cancers) - You have psychiatric conditions that prevent you from giving valid consent - You are unable to attend follow-up visits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTBlood sampling

Blood samples will be performed in fasted state for the controls and the patients. A single sample will be made in healthy subjects and several samples in patients: one before induction before surgery and then the second 4 weeks after surgery (+/- 1 week), then every 3 months for 18 months.


Locations(1)

Institut du Cancer de Montpellier - Val d'Aurelle

Montpellier, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04224064


Related Trials